135 related articles for article (PubMed ID: 34909758)
1. Pulmonary vascular system: A vulnerable target for COVID-19.
Ai J; Hong W; Wu M; Wei X
MedComm (2020); 2021 Dec; 2(4):531-547. PubMed ID: 34909758
[TBL] [Abstract][Full Text] [Related]
2. Recombinant ACE2 Expression Is Required for SARS-CoV-2 To Infect Primary Human Endothelial Cells and Induce Inflammatory and Procoagulative Responses.
Nascimento Conde J; Schutt WR; Gorbunova EE; Mackow ER
mBio; 2020 Dec; 11(6):. PubMed ID: 33310781
[TBL] [Abstract][Full Text] [Related]
3. The coagulopathy, endotheliopathy, and vasculitis of COVID-19.
Iba T; Connors JM; Levy JH
Inflamm Res; 2020 Dec; 69(12):1181-1189. PubMed ID: 32918567
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects.
Smadja DM; Mentzer SJ; Fontenay M; Laffan MA; Ackermann M; Helms J; Jonigk D; Chocron R; Pier GB; Gendron N; Pons S; Diehl JL; Margadant C; Guerin C; Huijbers EJM; Philippe A; Chapuis N; Nowak-Sliwinska P; Karagiannidis C; Sanchez O; Kümpers P; Skurnik D; Randi AM; Griffioen AW
Angiogenesis; 2021 Nov; 24(4):755-788. PubMed ID: 34184164
[TBL] [Abstract][Full Text] [Related]
5. Coronavirus Disease 2019 and Stroke: Clinical Manifestations and Pathophysiological Insights.
Divani AA; Andalib S; Di Napoli M; Lattanzi S; Hussain MS; Biller J; McCullough LD; Azarpazhooh MR; Seletska A; Mayer SA; Torbey M
J Stroke Cerebrovasc Dis; 2020 Aug; 29(8):104941. PubMed ID: 32689643
[TBL] [Abstract][Full Text] [Related]
6. Impaired coagulation, liver dysfunction and COVID-19: Discovering an intriguing relationship.
D'Ardes D; Boccatonda A; Cocco G; Fabiani S; Rossi I; Bucci M; Guagnano MT; Schiavone C; Cipollone F
World J Gastroenterol; 2022 Mar; 28(11):1102-1112. PubMed ID: 35431501
[TBL] [Abstract][Full Text] [Related]
7. COVID-19 Sepsis: Pathogenesis and Endothelial Molecular Mechanisms Based on "Two-Path Unifying Theory" of Hemostasis and Endotheliopathy-Associated Vascular Microthrombotic Disease, and Proposed Therapeutic Approach with Antimicrothrombotic Therapy.
Chang JC
Vasc Health Risk Manag; 2021; 17():273-298. PubMed ID: 34103921
[TBL] [Abstract][Full Text] [Related]
8. Linking ACE2 and angiotensin II to pulmonary immunovascular dysregulation in SARS-CoV-2 infection.
Seltzer S
Int J Infect Dis; 2020 Dec; 101():42-45. PubMed ID: 32950735
[TBL] [Abstract][Full Text] [Related]
9. Endothelial glycocalyx damage as a systemic inflammatory microvascular endotheliopathy in COVID-19.
Yamaoka-Tojo M
Biomed J; 2020 Oct; 43(5):399-413. PubMed ID: 33032965
[TBL] [Abstract][Full Text] [Related]
10. Endothelial dysfunction contributes to COVID-19-associated vascular inflammation and coagulopathy.
Zhang J; Tecson KM; McCullough PA
Rev Cardiovasc Med; 2020 Sep; 21(3):315-319. PubMed ID: 33070537
[TBL] [Abstract][Full Text] [Related]
11. Pulmonary Endothelial Dysfunction and Thrombotic Complications in Patients with COVID-19.
Rodríguez C; Luque N; Blanco I; Sebastian L; Barberà JA; Peinado VI; Tura-Ceide O
Am J Respir Cell Mol Biol; 2021 Apr; 64(4):407-415. PubMed ID: 33180562
[TBL] [Abstract][Full Text] [Related]
12. Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies.
Xu SW; Ilyas I; Weng JP
Acta Pharmacol Sin; 2023 Apr; 44(4):695-709. PubMed ID: 36253560
[TBL] [Abstract][Full Text] [Related]
13. Direct Activation of Endothelial Cells by SARS-CoV-2 Nucleocapsid Protein Is Blocked by Simvastatin.
Qian Y; Lei T; Patel PS; Lee CH; Monaghan-Nichols P; Xin HB; Qiu J; Fu M
J Virol; 2021 Nov; 95(23):e0139621. PubMed ID: 34549987
[TBL] [Abstract][Full Text] [Related]
14. Vascular Aging and COVID-19.
Badaras I; Laučytė-Cibulskienė A
Angiology; 2023 Apr; 74(4):308-316. PubMed ID: 36031949
[TBL] [Abstract][Full Text] [Related]
15. COVID-19 and the Vasculature: Current Aspects and Long-Term Consequences.
Martínez-Salazar B; Holwerda M; Stüdle C; Piragyte I; Mercader N; Engelhardt B; Rieben R; Döring Y
Front Cell Dev Biol; 2022; 10():824851. PubMed ID: 35242762
[TBL] [Abstract][Full Text] [Related]
16. IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra).
Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G; Toniato E
J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1623-1627. PubMed ID: 32744052
[TBL] [Abstract][Full Text] [Related]
17. Endothelial contribution to COVID-19: an update on mechanisms and therapeutic implications.
Ma Z; Yang KY; Huang Y; Lui KO
J Mol Cell Cardiol; 2022 Mar; 164():69-82. PubMed ID: 34838588
[TBL] [Abstract][Full Text] [Related]
18. From acute SARS-CoV-2 infection to pulmonary hypertension.
Eroume À Egom E; Shiwani HA; Nouthe B
Front Physiol; 2022; 13():1023758. PubMed ID: 36601347
[TBL] [Abstract][Full Text] [Related]
19. Endothelial Dysfunction as a Primary Consequence of SARS-CoV-2 Infection.
Mezoh G; Crowther NJ
Adv Exp Med Biol; 2021; 1321():33-43. PubMed ID: 33656711
[TBL] [Abstract][Full Text] [Related]
20. DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications?
Valencia I; Peiró C; Lorenzo Ó; Sánchez-Ferrer CF; Eckel J; Romacho T
Front Pharmacol; 2020; 11():1161. PubMed ID: 32848769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
